InVivo Therapeutics
-
Financial
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
October 7, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with…
Read More » -
Biologics
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
July 13, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with…
Read More » -
Neuro
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
Manuscript details patient outcomes through 24-month follow up visit June 8, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today…
Read More » -
Spine
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
Topline data expected to be reported in Q1 2023 June 2, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV),…
Read More » -
Financial
InVivo Therapeutics Announces Reverse Stock Split
April 14, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common…
Read More » -
Financial
InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
October 26, 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering…
Read More » -
Financial
InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 17, 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its previously announced registered direct offering…
Read More » -
Financial
InVivo Therapeutics Announces Closing of $7.0 Million Public Offering
March 11, 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering…
Read More » -
Biologics
InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors
November 12, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the…
Read More » -
Financial
InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update
April 01, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2018.…
Read More » -
Financial
InVivo Therapeutics Announces Richard Christopher as CFO and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 14, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus…
Read More » -
Financial
InVivo Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
November 08, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the…
Read More » -
Biologics
InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.
October 02, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a…
Read More » -
Financial
InVivo Therapeutics Reports 2018 Second Quarter Financial Results
August 07, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the…
Read More » -
Financial
InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering
June 21, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403…
Read More »